Results from the ongoing phase 2 study BGBC008 trial (NCT03184571) of bemcentinib (BGB324) and pembrolizumab (Keytruda) in patients with checkpoint inhibitor (CPI)–naïve and CPI-refractory composite AXL (cAXL)–positive non–small cell lung cancer (NSCLC) support the continued development of AXL inhibition with bemcentinib in order to extend the efficacy of immunotherapy in biomarker-selected refractory NSCLC.
Overall, the trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in this patient population.
In this single-arm, 2-stage study, patients were treated with bemcentinib at a dose of 200mg per day and pembrolizumab at a dose of 200 mg every 3 weeks. The study includes 3 patient cohorts. Cohort A consists of immunotherapy-naïve patients who failed on prior chemotherapy; cohort B includes patients progressing…
